<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02467582</url>
  </required_header>
  <id_info>
    <org_study_id>SAKK 41/13 - Aspirin</org_study_id>
    <secondary_id>SNCTP000001339</secondary_id>
    <secondary_id>2015-001482-57</secondary_id>
    <nct_id>NCT02467582</nct_id>
  </id_info>
  <brief_title>Adjuvant Aspirin Treatment for Colon Cancer Patients</brief_title>
  <official_title>Adjuvant Aspirin Treatment in PIK3CA Mutated Colon Cancer Patients. A Randomized, Double-blinded, Placebo-controlled, Phase III Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Swiss Group for Clinical Cancer Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>European Organisation for Research and Treatment of Cancer - EORTC</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Central European Society for Anticancer Drug Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Swiss Group for Clinical Cancer Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Following complete resection of their primary tumor, potentially eligible stage II or stage&#xD;
      III colon cancer patients will undergo central PIK3CA testing. Patients with somatic&#xD;
      mutations will be 2:1 randomized to daily aspirin 100 mg versus placebo for a total of 3&#xD;
      years or until disease recurrence, patient death or withdrawal of consent, whichever occurs&#xD;
      first. Patients will be followed up for 10 years from the date of surgery.&#xD;
&#xD;
      The intake of aspirin or placebo is independent of adjuvant chemotherapy, and does not impact&#xD;
      on the indication to give (or not to give) adjuvant chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Colorectal cancer is the third most common malignancy for both women and men and is&#xD;
      responsible for almost 10% of all cancer death. Despite complete removal of the tumor and use&#xD;
      of adjuvant chemotherapy, up to 25% of patients with stage II colon cancer and up to 50% of&#xD;
      patients with stage III disease will suffer from recurrences, which is associated with poor&#xD;
      prognosis.&#xD;
&#xD;
      Several retrospective observations have documented a favorable effect of long-term intake of&#xD;
      oral aspirin for the prevention of colorectal cancer in different clinical situations.&#xD;
      Regular intake of aspirin after the diagnosis of colorectal cancer may also be associated&#xD;
      with a lower risk of colorectal cancer-specific and overall mortality. Two recent&#xD;
      publications in prestigious medical journals provided retrospective evidence that patients&#xD;
      with PIK3CA-mutated colon cancer may derive a very substantial benefit from daily oral&#xD;
      aspirin. Both analyses showed a roughly 85% reduction of the risk for tumor relapse compared&#xD;
      to patients who did not take aspirin. However, a potential selection bias in these&#xD;
      retrospective analyses cannot be excluded with certainty. These extremely interesting and&#xD;
      intriguing findings must be confirmed in a randomized controlled trial to potentially change&#xD;
      clinical practice.&#xD;
&#xD;
      The trial objective is to demonstrate a statistically significant and clinically relevant&#xD;
      disease-free survival benefit in stage II and III PIK3CA mutated colon cancer patients taking&#xD;
      daily adjuvant aspirin for 3 years.&#xD;
&#xD;
      Patients with resected colon cancer stage II or stage III bearing somatic mutations in exon 9&#xD;
      or 20 of PIK3CA will be 2:1 randomized to daily adjuvant aspirin 100 mg versus placebo for a&#xD;
      total of 3 years or until disease recurrence, patient death or withdrawal of consent,&#xD;
      whichever occurs first. Patients will be followed up for up to 10 years from the date of&#xD;
      surgery. The intake of aspirin or placebo is independent of adjuvant chemotherapy, and does&#xD;
      not impact on the indication to give (or not to give) adjuvant chemotherapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 9, 2016</start_date>
  <completion_date type="Anticipated">June 2029</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>at 6 years after first patient in.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence (TTR)</measure>
    <time_frame>at 6 years after first patient in.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>at 6 years after first patient in and trial termination (13 years after first patient in)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer-specific survival (CSS)</measure>
    <time_frame>at 6 years after first patient in and trial termination (13 years after first patient in).</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs)</measure>
    <time_frame>at 6 years after first patient in.</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">185</enrollment>
  <condition>Colon Cancer</condition>
  <arm_group>
    <arm_group_label>Aspirin 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Asprin 100 mg daily for 3 years standard chemo if indicated</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo daily for 3 years standard chemo if indicated</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>Aspirin 100 mg daily</description>
    <arm_group_label>Aspirin 100 mg</arm_group_label>
    <other_name>acetylsalicylic acid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent according to ICH/GCP regulations before inclusion and prior&#xD;
             to any trial-related investigations.&#xD;
&#xD;
          -  Histologically confirmed diagnosis of adenocarcinoma of the colon.&#xD;
&#xD;
          -  Stage II (pT3/T4 N0 cM0) or stage III (pTx pN+ cM0) colon cancer.&#xD;
&#xD;
          -  Availability of cancer tissue for central molecular testing.&#xD;
&#xD;
          -  Presence of predefined, activating PIK3CA mutation in exons 9 or 20 (centrally&#xD;
             assessed).&#xD;
&#xD;
          -  Complete resection of the primary tumor (R0) within 14 weeks maximum before&#xD;
             registration.&#xD;
&#xD;
          -  WHO performance status 0-2.&#xD;
&#xD;
          -  Age between 18-80 years.&#xD;
&#xD;
          -  Adequate hematological values: hemoglobin ≥ 80 g/L, platelets ≥ 50 x 109/L.&#xD;
&#xD;
          -  Adequate hepatic function: total bilirubin ≤1.5xULN, AST ≤2.5xULN, ALT ≤2.5xULN, AP&#xD;
             ≤2.5xULN.&#xD;
&#xD;
          -  Calculated creatinine clearance &gt; 30 mL/min, according to the formula of&#xD;
             Cockcroft-Gault.&#xD;
&#xD;
          -  Women with child-bearing potential are using effective contraception, are not pregnant&#xD;
             or lactating and agree not to become pregnant during trial treatment. A negative&#xD;
             pregnancy test before inclusion (within 7 days) into the trial is required for all&#xD;
             women with child-bearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Previous or concomitant malignancy within 3 years of registration, except for&#xD;
             adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer.&#xD;
&#xD;
          -  Multiple adenocarcinomas of the colon.&#xD;
&#xD;
          -  Rectal cancer (defined as distance from anal verge to proximal/oral tumor edge ≤15&#xD;
             cm).&#xD;
&#xD;
          -  Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or&#xD;
             IV, unstable angina pectoris, history of myocardial infarction) within three months&#xD;
             prior to registration.&#xD;
&#xD;
          -  Systemic rheumatic diseases or degenerative disorders affecting the musculoskeletal&#xD;
             system with a relevant risk of requiring treatment with NSAIDs in the future.&#xD;
&#xD;
          -  Comorbidities that require regular (i.e. more than 3x per month, any dose) intake of&#xD;
             acetylsalicylic acid or other NSAIDs or COX-2 inhibitors.&#xD;
&#xD;
          -  Clinically relevant upper gastro-intestinal bleeding within 12 months prior to&#xD;
             registration.&#xD;
&#xD;
          -  Presence of any bleeding disorder that is an absolute contraindication to the use of&#xD;
             aspirin.&#xD;
&#xD;
          -  General tendency to hypersensitivity and history of asthma triggered by salicylates or&#xD;
             substances with a similar mechanism of action, and non-steroidal anti-inflammatory&#xD;
             drugs in particular&#xD;
&#xD;
          -  Any serious underlying medical condition, at the judgment of the investigator, which&#xD;
             could impair the ability of the patient to participate in the trial (e.g. uncontrolled&#xD;
             infection, active autoimmune disease, uncontrolled diabetes).&#xD;
&#xD;
          -  Concurrent treatment with other experimental drugs or treatment in an interventional&#xD;
             clinical trial within 30 days prior to trial entry. Concomitant use of adjuvant&#xD;
             chemotherapy for stage III and high risk stage II colon cancer according to&#xD;
             international treatment guidelines is allowed (chemotherapy regimens include&#xD;
             intravenous 5-fluorouracil or oral capecitabine either alone or in combination with&#xD;
             intravenous oxaliplatin).&#xD;
&#xD;
          -  Psychiatric disorder precluding understanding of trial information, giving informed&#xD;
             consent or interfering with compliance for oral drug intake.&#xD;
&#xD;
          -  Any familial, sociological or geographical condition potentially hampering proper&#xD;
             staging and compliance with the trial protocol.&#xD;
&#xD;
          -  Known or suspected hypersensitivity to any component of the trial drug or any agent&#xD;
             given in association with this trial.&#xD;
&#xD;
          -  Known galactose-1-phosphate uridyl transferase deficiency, UDP galactose 4 epimerase&#xD;
             deficiency, galactokinase deficiency, orFanconi-Bickel syndrome, congenital lactase&#xD;
             deficiency,or glucose-galactose malabsorption (due to the lactose-containing placebo).&#xD;
&#xD;
          -  Any concomitant drugs contraindicated for use with the trial drug according to the&#xD;
             approved product information.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ulrich Güller, Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Cantonal Hospital of St. Gallen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Universitaire Brugmann</name>
      <address>
        <city>Brussels</city>
        <zip>1020</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Ziekenhuis Brussel</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Jolimont</name>
      <address>
        <city>Haine-Saint-Paul</city>
        <zip>7100</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHC - Clinique Saint-Joseph</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Az Damiaan</name>
      <address>
        <city>Oostende</city>
        <zip>8400</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Turnhout - Campus Sint-Elisabeth</name>
      <address>
        <city>Turnhout</city>
        <zip>2300</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spandau Vivantes Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13585</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fürst-Stirum-Klinik Bruchsal</name>
      <address>
        <city>Bruchsal</city>
        <zip>76646</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Dresden</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Essen Mitte</name>
      <address>
        <city>Essen</city>
        <zip>45136</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>pioh Frechen</name>
      <address>
        <city>Frechen</city>
        <zip>50226</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis und Tagesklinik - Medizinische Management GmbH</name>
      <address>
        <city>Friedrichshafen</city>
        <zip>88045</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Überörtliche Gemeinschaftspraxis - Schwerpunkt Haematologie, internistische Onkologie &amp; Palliativmedizin</name>
      <address>
        <city>Hamburg</city>
        <zip>20259</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Hochschule Hannover</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologische Schwerpunktpraxis Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>pioh KÖLN</name>
      <address>
        <city>Köln</city>
        <zip>50674</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologie UnterEms</name>
      <address>
        <city>Leer</city>
        <zip>26789</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Ludwigsburg</name>
      <address>
        <city>Ludwigsburg</city>
        <zip>71640</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mannheim</name>
      <address>
        <city>Mannheim</city>
        <zip>68135</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH - Krankenhaus St. Franziskus</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Klinik und Poliklinik III - Universitätsklinik</name>
      <address>
        <city>München</city>
        <zip>83177</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nuernberg</name>
      <address>
        <city>Nuernberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pi.Tri-Studien GmbH</name>
      <address>
        <city>Offenburg</city>
        <zip>77654</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CaritasKlinikum Saarbrücken</name>
      <address>
        <city>Saarbrücken</city>
        <zip>66113</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marienhospital</name>
      <address>
        <city>Stuttgart</city>
        <zip>70199</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik für Innere Medizin I</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Studiengesellschaft NORD-WEST GmbH - Praxis Aurich</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Studiengesellschaft NORD-WEST GmbH</name>
      <address>
        <city>Westerstede</city>
        <zip>26655</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. László Teaching Hospital</name>
      <address>
        <city>Budapest</city>
        <zip>H - 1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Aarau</name>
      <address>
        <city>Aarau</city>
        <zip>CH-5001</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Baden</name>
      <address>
        <city>Baden</city>
        <zip>5404</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4031</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Claraspital Basel</name>
      <address>
        <city>Basel</city>
        <zip>4058</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IOSI, Ospedale San Giovanni</name>
      <address>
        <city>Bellinzona</city>
        <zip>6500</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinik Engeried / Oncocare</name>
      <address>
        <city>Bern</city>
        <zip>3012</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inselspital Bern</name>
      <address>
        <city>Bern</city>
        <zip>CH-3010</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Biel</name>
      <address>
        <city>Biel</city>
        <zip>CH-2501</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spitalzentrum Oberwallis</name>
      <address>
        <city>Brig</city>
        <zip>3900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Graubünden</name>
      <address>
        <city>Chur</city>
        <zip>7000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HFR-Hôpital cantonal</name>
      <address>
        <city>Fribourg</city>
        <zip>1708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCAC Fribourg</name>
      <address>
        <city>Fribourg</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinique de Genolier</name>
      <address>
        <city>Genolier</city>
        <zip>1272</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopitaux Universitaires de Geneve</name>
      <address>
        <city>Genève 14</city>
        <zip>1211</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCAC Lausanne</name>
      <address>
        <city>Lausanne</city>
        <zip>1004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <zip>CH-1011</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Liestal</name>
      <address>
        <city>Liestal</city>
        <zip>4410</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Luganese</name>
      <address>
        <city>Lugano</city>
        <zip>6900</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Luzern</name>
      <address>
        <city>Luzern</city>
        <zip>6000</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologie Zentrum Spital Männedorf</name>
      <address>
        <city>Manno</city>
        <zip>8708</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Thurgau</name>
      <address>
        <city>Munsterlingen</city>
        <zip>8596</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital de Pourtalès</name>
      <address>
        <city>Neuchâtel</city>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Olten</name>
      <address>
        <city>Olten</city>
        <zip>CH-4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spital Limmattal</name>
      <address>
        <city>Schlieren</city>
        <zip>8952</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital du Valais Sion</name>
      <address>
        <city>Sion</city>
        <zip>1951</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bürgerspital Solothurn - Onkologiezentrum</name>
      <address>
        <city>Solothurn</city>
        <zip>4600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <zip>9007</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SpitalSTS AG Simmental-Thun-Saanenland</name>
      <address>
        <city>Thun</city>
        <zip>3600</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8400</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Hospital Triemli</name>
      <address>
        <city>Zurich</city>
        <zip>CH-8063</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>June 5, 2015</study_first_submitted>
  <study_first_submitted_qc>June 8, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 10, 2015</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aspirin</keyword>
  <keyword>colon cancer</keyword>
  <keyword>stage II</keyword>
  <keyword>stage III</keyword>
  <keyword>PIK3CA</keyword>
  <keyword>double-blind</keyword>
  <keyword>placebo</keyword>
  <keyword>Adjuvant Treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

